An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult male

Trial Profile

An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult male

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Topiroxostat (Primary) ; Warfarin
  • Indications Diabetic nephropathies; Gout; Hyperuricaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sanwa Kagaku Kenkyusho
  • Most Recent Events

    • 02 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top